新诊断2型糖尿病患者门冬胰岛素强化治疗的临床观察

Clinical Observation on the Strengthening Treatment of Newly Diagnosed Type 2 Diabetic Patients with Insulin Aspart

目的 探究门冬胰岛素与传统生物合成人胰岛素对2型糖尿病的治疗疗效和安全性上的差异.方法 截取我院2012-09~2013-03间收治的共70例2型糖尿病患者,按随机数字表法分为治疗组（门冬胰岛素）及对照组（生物合成人胰岛素）,两组均采取4次/d的胰岛素降糖强化方案治疗.其中,治疗组在三餐前10 min内皮下注射门冬胰岛素,在晚上10时皮下注射精蛋白生物合成的人胰岛素;对照组在三餐前30 min内皮下注射生物合成的人胰岛素,在晚上10时皮下注射精蛋白生物合成的人胰岛素.对比两组患者间临床资料差异性,包括两组的低血糖发生率、血糖控制情况、胰岛素使用量和住院时间.结果 治疗组和对照组患者治疗后空腹和餐后血糖降低明显（P＜0.05）;治疗组患者低血糖发生率显著低于对照组（P＜0.05）;治疗组和对照组患者胰岛素的使用量和住院时间的差异无统计学意义（P＞0.05）.结论 与生物合成人胰岛素相比,门冬胰岛素能更安全地用于2型糖尿病患者的血糖控制.

Objective To detect the difference of clinical effect and safety between human insulin and insulin aspart for the treatment of type 2 diabetes. Methods In the hospital from September, 2012 to March, 2013, a total of 80 newly diagnosed type 2 diabetic patients were randomly divided into 2 groups and patients from both group received intensive insulin treatment 4 times per day. Patients from the experimental group were injected with insulin aspart thrice before meal and were then injected with isophane protamine human insulin at 10：00 pm. Patients from the control group were injected with human insulin and then were injected with isophane protamine human insulin at 10：00 pm. Then the occurrence of hypoglycemia , blood glucose lever , dosage of insulin and the total therapeutic time were detected to compare the difference of clinical effect and safety between the two groups. Results The levels of blood glucose before and after meal in both groups decrease remarkably （ P 〈 0.05 ） ; The incidence of hypoglycemia in the experimental group was remarkably lower than that of the control group （ P 〈 0. 05） ; The difference of therapeutic time and dosage of insulin usage had no statistical importance between the two groups. Conclusion Compared with human insulin, insulin aspart may be safer and more effective in the control of blood glucose and treatment of type 2 diabetes.